News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GlaxoSmithKline’s Prescription-Strength Fish Oil Drug, Lovaza Fails in Atrial Fibrillation Study
November 16, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHICAGO, Nov 15 (Reuters) - Taking a high dose of fish oil does not prevent symptoms of atrial fibrillation, a common heart rhythm problem that can cause strokes, U.S. researchers said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
GSK
MORE ON THIS TOPIC
Cardiovascular disease
Tenax shares nosedive as heart failure drug fails in Phase 3
August 10, 2026
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH AGC BIOLOGICS
From ex vivo to in vivo: Shaping the next generation of viral vector manufacturing
August 10, 2026
·
8 min read
·
Jennifer C. Smith-Parker
Cancer
Replimune to ride wave of physician support to launch advanced melanoma therapy
August 7, 2026
·
4 min read
·
Annalee Armstrong
Gene Therapy
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
August 7, 2026
·
2 min read
·
Tristan Manalac
